# Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)

> **NCT03569033** · PHASE2 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 46 (actual)

## Conditions studied

- Acute Cough

## Interventions

- **DRUG:** Gefapixant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03569033
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-04
- **Primary completion:** 2018-10-31
- **Final completion:** 2018-11-19
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** The data did not support study endpoints for acute cough, based on an interim efficacy analysis; not due to safety concerns.
- **Last updated:** 2019-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03569033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03569033, "Study of Gefapixant (MK-7264) in Acute Cough for Participants With Induced Viral Upper Respiratory Tract Infection (URTI) (MK-7264-013)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03569033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*